InMed Pharmaceuticals Reverse Stock Split
InMed Pharmaceuticals completed a 1-for-10 reverse stock split (consolidation), reducing its outstanding shares from approximately 5.49 million to 549,374. The company also legally changed its name to Mentari Therapeutics, Inc. and confirmed shareholder approval of all matters at its 2026 Annual General and Special Meeting.